Peptide ReadinessJoin the beta
Back to database

FDA APPROVED COMPARATOR

Semaglutide

A benchmark for how a peptide therapeutic moves from pivotal development through licensing, HTA and large scale clinical adoption.

Conceptual three-dimensional molecular signature for Semaglutide; not an exact chemical structure.
GLP-1 receptor agonist peptideConceptual molecular signature · not an exact chemical structure
Record version 1.0Last verified 5 September 2026Evidence grade AAuthorised product precedent
FDA STATUS

FDA approved in specific products and indications

MHRA / UK LICENCE

UK authorised in specific products and indications

NICE STATUS

NICE recommendations exist for defined diabetes and obesity uses

NHS ACCESS

NHS access exists within NICE criteria and commissioned pathways

PRIVATE LAWFUL USE CONTEXT

Lawful private prescribing is product, indication and prescriber specific

EVIDENCE MATURITY

Authorised medicine with large Phase 3 and post marketing evidence base

DEVELOPMENT PHASE

Authorised product precedent

MARKET EXPOSURE

Very high

PROFESSIONAL RELEVANCE

Use as the reference pathway for evidence, pharmacovigilance, commissioning and implementation, not as evidence for unrelated experimental peptides.

Product, formulation and indication

Wegovy

UK · Injection

Chronic weight management

Ozempic

UK · Injection

Type 2 diabetes

Rybelsus

UK · Tablet

Type 2 diabetes

Status history

Production baseline verification recorded.

Established FDA approved peptide medicine

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.